Japón - inglés - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - bezafibrate - white to yellowish white tablet, diameter: 9.1 mm, thickness: 4.8 mm

Japón - inglés - すりの適正使用協議会 RAD-AR Council, Japan

fuso pharmaceutical industries, ltd. - bezafibrate - white to yellowish white tablet, diameter: 9.1 mm, thickness: 4.8 mm

Japón - inglés - すりの適正使用協議会 RAD-AR Council, Japan

nihon generic co.,ltd - bezafibrate - white to yellowish white tablet, diameter: 7.1 mm, thickness: 3.8 mm

Japón - inglés - すりの適正使用協議会 RAD-AR Council, Japan

nihon generic co.,ltd - bezafibrate - white tablet, diameter: 9.1 mm, thickness: 4.2 mm

Japón - inglés - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - bezafibrate - white to yellowish white tablet, diameter: 7.1 mm, thickness: 3.8 mm

Japón - inglés - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - bezafibrate - white to yellowish white tablet, diameter: 9.0 mm, thickness: 4.2 mm

Namibia - inglés - Namibia Medicines Regulatory Council

pharma dynamics (pty) ltd - bezafibrate - tablets - each slow release tablet contains bezafibrate 400,0 mg

Namibia - inglés - Namibia Medicines Regulatory Council

rolab (pty) ltd - bezafibrate - tablets - each tablet contains bezafibrate 400 mg

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - bezafibrate 200mg; bezafibrate 200mg - film coated tablet - 200 mg - active: bezafibrate 200mg excipient: colloidal silicon dioxide macrogols magnesium stearate maize starch microcrystalline cellulose opadry white polyvinyl alcohol purified talc sodium starch glycolate starch titanium dioxide active: bezafibrate 200mg excipient: colloidal silicon dioxide kaolin lactose monohydrate macrogols magnesium stearate maize starch methacrylic acid copolymer microcrystalline cellulose polysorbate 80 purified talc sodium citrate dihydrate sodium starch glycolate titanium dioxide - - primary hyperlipidaemia types iia, iib, iii, iv and v (fredrickson classification) corresponding to groups i, ii and iii of the european atherosclerosis society guidelines – when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. - secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).

Estados Unidos - inglés - NLM (National Library of Medicine)

bluebay shandong co.,ltd - bezafibrate (unii: y9449q51xh) (bezafibrate - unii:y9449q51xh) -